Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care

Best Practice and Research: Clinical Gastroenterology

Volumn 30, Issue 4, 2016, Pages 603-616

  Méndez Romero, Alejandra ^a   de Man, Robert A ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Liver; Metastases; Stereotactic body radiation therapy

Indexed keywords

BILE DUCT CARCINOMA; CANCER CONTROL; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; PATIENT CARE; QUALITY OF LIFE; RADIATION DOSE; RADIATION HAZARD; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; LIVER NEOPLASMS; METASTASIS; PROCEDURES; RADIOSURGERY; SECONDARY;

HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; QUALITY OF LIFE; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84979573647     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2016.06.003     Document Type: Review

References (80)

1. [1] Borgelt, B.B., Gelber, R., Brady, L.W., Griffin, T., Hendrickson, F.R., The palliation of hepatic metastases: results of the radiation therapy oncology group pilot study. Int J Radiat Oncol Biol Phys 7:5 (1981), 587–591.
2. [2] Emami, B., Lyman, J., Brown, A., Coia, L., Goitein, M., Munzenrider, J.E., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:1 (5-15-1991), 109–122.
3. [3] Lax, I., Blomgren, H., Naslund, I., Svanstrom, R., Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:6 (1994), 677–683.
4. [4] McGinn, C.J., Ten Haken, R.K., Ensminger, W.D., Walker, S., Wang, S., Lawrence, T.S., Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 16:6 (1998), 2246–2252.
5. [5] Potters, L., Steinberg, M., Rose, C., Timmerman, R., Ryu, S., Hevezi, J.M., et al. American Society for therapeutic radiology and oncology and American College of radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 60:4 (11-15-2004), 1026–1032.
6. [6] Song, C.W., Lee, Y.J., Griffin, R.J., Park, I., Koonce, N.A., Hui, S., et al. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93:1 (9-1-2015), 166–172.
7. [7] Goodman, B.D., Mannina, E.M., Althouse, S.K., Maluccio, M.A., Cardenes, H.R., Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 6:2 (2016), 86–95.
8. [8] Goodman, K.A., Wiegner, E.A., Maturen, K.E., Zhang, Z., Mo, Q., Yang, G., et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:2 (10-1-2010), 486–493.
9. [9] Lee, M.T., Kim, J.J., Dinniwell, R., Brierley, J., Lockwood, G., Wong, R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:10 (4-1-2009), 1585–1591.
10. [10] Mendez, R.A., Wunderink, W., Hussain, S.M., de Pooter, J.A., Heijmen, B.J., Nowak, P.C., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45:7 (2006), 831–837.
11. [11] Scorsetti, M., Comito, T., Tozzi, A., Navarria, P., Fogliata, A., Clerici, E., et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141:3 (2015), 543–553.
12. [12] Stintzing, S., Hoffmann, R.T., Heinemann, V., Kufeld, M., Muacevic, A., Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer 46:6 (2010), 1026–1032.
13. [13] Ambrosino, G., Polistina, F., Costantin, G., Francescon, P., Guglielmi, R., Zanco, P., et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:8 (2009), 3381–3384.
14. [14] Meyer, J.J., Foster, R.D., Lev-Cohain, N., Yokoo, T., Dong, Y., Schwarz, R.E., et al. A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases. Ann Surg Oncol 23:1 (2016), 218–224.
15. [15] van der Pool, A.E., Mendez, R.A., Wunderink, W., Heijmen, B.J., Levendag, P.C., Verhoef, C., et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:3 (2010), 377–382.
16. Rusthoven, K.E., Kavanagh, B.D., Cardenes, H., Stieber, V.W., Burri, S.H., Feigenberg, S.J., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:10 (4-1-2009), 1572–1578.
17. [17] Rule, W., Timmerman, R., Tong, L., Abdulrahman, R., Meyer, J., Boike, T., et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:4 (2011), 1081–1087.
18. [18] Vautravers-Dewas, C., Dewas, S., Bonodeau, F., Adenis, A., Lacornerie, T., Penel, N., et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?. Int J Radiat Oncol Biol Phys 81:3 (11-1-2011), e39–e47.
19. [19] Chang, D.T., Swaminath, A., Kozak, M., Weintraub, J., Koong, A.C., Kim, J., et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:17 (9-1-2011), 4060–4069.
20. [20] McCammon, R., Schefter, T.E., Gaspar, L.E., Zaemisch, R., Gravdahl, D., Kavanagh, B., Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 73:1 (1-1-2009), 112–118.
21. [21] Wulf, J., Guckenberger, M., Haedinger, U., Oppitz, U., Mueller, G., Baier, K., et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45:7 (2006), 838–847.
22. Ohri, N., Jackson, A., Mendez Romero, A., Miften, M., Ten Haken, R.K., Dawson, L.A., et al. Local control following stereotactic body radiotherapy for liver tumors: a preliminary report of the AAPM Working Group for SBRT. Int J Radiat Oncol Biol Phys, 90(1), 9-1-2014, S52.
23. [23] Schefter, T.E., Kavanagh, B.D., Timmerman, R.D., Cardenes, H.R., Baron, A., Gaspar, L.E., A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:5 (8-1-2005), 1371–1378.
24. [24] Hoyer, M., Roed, H., Traberg, H.A., Ohlhuis, L., Petersen, J., Nellemann, H., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:7 (2006), 823–830.
25. Scorsetti, M., Arcangeli, S., Tozzi, A., Comito, T., Alongi, F., Navarria, P., et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:2 (6-1-2013), 336–342.
26. [26] Stintzing, S., Grothe, A., Hendrich, S., Hoffmann, R.T., Heinemann, V., Rentsch, M., et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol 52:5 (2013), 971–977.
27. [27] EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:4 (2012), 908–943.
28. [28] Fong, Z.V., Tanabe, K.K., The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 120:18 (9-15-2014), 2824–2838.
29. [29] Iwata, H., Shibamoto, Y., Hashizume, C., Mori, Y., Kobayashi, T., Hayashi, N., et al. Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 9:6 (2010), 619–627.
30. [30] Kimura, T., Aikata, H., Takahashi, S., Takahashi, I., Nishibuchi, I., Doi, Y., et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 45:4 (2015), 378–386.
31. [31] Louis, C., Dewas, S., Mirabel, X., Lacornerie, T., Adenis, A., Bonodeau, F., et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 9:5 (2010), 479–487.
32. [32] Sanuki, N., Takeda, A., Oku, Y., Mizuno, T., Aoki, Y., Eriguchi, T., et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 53:3 (2014), 399–404.
33. [33] Su, T.S., Liang, P., Lu, H.Z., Liang, J., Gao, Y.C., Zhou, Y., et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 113:2 (2016), 181–187.
34. Andolino, D.L., Johnson, C.S., Maluccio, M., Kwo, P., Tector, A.J., Zook, J., et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81:4 (11-15-2011), e447–e453.
35. [35] Cardenes, H.R., Price, T.R., Perkins, S.M., Maluccio, M., Kwo, P., Breen, T.E., et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12:3 (2010), 218–225.
36. Kang, J.K., Kim, M.S., Cho, C.K., Yang, K.M., Yoo, H.J., Kim, J.H., et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 118:21 (11-1-2012), 5424–5431.
37. [37] Seo, Y.S., Kim, M.S., Yoo, S.Y., Cho, C.K., Choi, C.W., Kim, J.H., et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:3 (9-1-2010), 209–214.
38. [38] Honda, Y., Kimura, T., Aikata, H., Kobayashi, T., Fukuhara, T., Masaki, K., et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol 28:3 (2013), 530–536.
39. [39] Bibault, J.E., Dewas, S., Vautravers-Dewas, C., Hollebecque, A., Jarraya, H., Lacornerie, T., et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One, 8(10), 2013, e77472.
40. Bujold, A., Massey, C.A., Kim, J.J., Brierley, J., Cho, C., Wong, R.K., et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:13 (5-1-2013), 1631–1639.
41. [41] Huang, B.S., Tsang, N.M., Lin, S.M., Lin, D.Y., Lien, J.M., Lin, C.C., et al. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: tumor responses and toxicities. Oncol Lett 6:5 (2013), 1514–1520.
42. [42] Wigg, A.J., Palumbo, K., Wigg, D.R., Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. J Gastroenterol Hepatol 25:4 (2010), 664–671.
43. [43] Culleton, S., Jiang, H., Haddad, C.R., Kim, J., Brierley, J., Brade, A., et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 111:3 (2014), 412–417.
44. [44] Cheng, J.C., Wu, J.K., Lee, P.C., Liu, H.S., Jian, J.J., Lin, Y.M., et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60:5 (12-1-2004), 1502–1509.
45. [45] Dawson, L.A., Normolle, D., Balter, J.M., McGinn, C.J., Lawrence, T.S., Ten Haken, R.K., Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:4 (7-15-2002), 810–821.
46. [46] Liang, S.X., Zhu, X.D., Xu, Z.Y., Zhu, J., Zhao, J.D., Lu, H.J., et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 65:2 (6-1-2006), 426–434.
47. [47] Jang, J.W., Kwon, J.H., You, C.R., Kim, J.D., Woo, H.Y., Bae, S.H., et al. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther 16:7 (2011), 969–977.
48. [48] Kim, J.H., Park, J.W., Kim, T.H., Koh, D.W., Lee, W.J., Kim, C.M., Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 69:3 (11-1-2007), 813–819.
49. [49] Park, J.H., Yoon, S.M., Lim, Y.S., Kim, S.Y., Shim, J.H., Kim, K.M., et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. J Gastroenterol Hepatol 28:10 (2013), 1638–1642.
50. [50] Lasley, F.D., Mannina, E.M., Johnson, C.S., Perkins, S.M., Althouse, S., Maluccio, M., et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 5:5 (2015), e443–e449.
51. [51] Sandroussi, C., Dawson, L.A., Lee, M., Guindi, M., Fischer, S., Ghanekar, A., et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 23:3 (3-1-2010), 299–306.
52. [52] Katz, A.W., Chawla, S., Qu, Z., Kashyap, R., Milano, M.T., Hezel, A.F., Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 83:3 (12-13-2011), 895–900.
53. [53] Facciuto, M.E., Singh, M.K., Rochon, C., Sharma, J., Gimenez, C., Katta, U., et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 105:7 (6-1-2012), 692–698.
54. [54] Sanuki, N., Takeda, A., Oku, Y., Eriguchi, T., Nishimura, S., Aoki, Y., et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 45:5 (2015), 540–547.
55. [55] Barney, B.M., Markovic, S.N., Laack, N.N., Miller, R.C., Sarkaria, J.N., Macdonald, O.K., et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys 87:1 (9-1-2013), 73–80.
56. [56] Dawson, L.A., Brade, A., Cho, C., Kim, J., Dinniwell, R., Wong, R., et al. Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma. 10-28-2012 Abstract book.
57. [57] Liao, M., Huang, J., Zhang, T., Wu, H., Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One, 8(7), 2013, e68453.
58. [58] Huang, W.Y., Jen, Y.M., Lee, M.S., Chang, L.P., Chen, C.M., Ko, K.H., et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84:2 (10-1-2012), 355–361.
59. [59] Wahl, D.R., Stenmark, M.H., Tao, Y., Pollom, E.L., Caoili, E.M., Lawrence, T.S., et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34:5 (2-10-2016), 452–459.
60. [60] O'Connor, J.K., Trotter, J., Davis, G.L., Jane Dempster, R.N., Klintmalm, G.B., Goldstein, R.M., Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 18:8 (3-29-2012), 949–954.
61. [61] Mahadevan, A., Dagoglu, N., Mancias, J., Raven, K., Khwaja, K., Tseng, J.F., et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 6:11 (2015), 1099–1104.
62. [62] Jung, dH., Kim, M.S., Cho, C.K., Yoo, H.J., Jang, W.I., Seo, Y.S., et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 32:3 (2014), 163–169.
63. [63] Barney, B.M., Olivier, K.R., Miller, R.C., Haddock, M.G., Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol, 7, 2012, 67.
64. [64] Kopek, N., Holt, M.I., Hansen, A.T., Hoyer, M., Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 94:1 (2010), 47–52.
65. [65] Momm, F., Schubert, E., Henne, K., Hodapp, N., Frommhold, H., Harder, J., et al. Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother Oncol 95:1 (2010), 99–102.
66. Polistina, F.A., Guglielmi, R., Baiocchi, C., Francescon, P., Scalchi, P., Febbraro, A., et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 99:2 (2011), 120–123.
67. Tao, R., Krishnan, S., Bhosale, P.R., Javle, M.M., Aloia, T.A., Shroff, R.T., et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 34:3 (1-20-2016), 219–226.
68. [68] Tse, R.V., Hawkins, M., Lockwood, G., Kim, J.J., Cummings, B., Knox, J., et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:4 (2-1-2008), 657–664.
69. [69] Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:14 (4-8-2010), 1273–1281.
70. [70] Welling, T.H., Feng, M., Wan, S., Hwang, S.Y., Volk, M.L., Lawrence, T.S., et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl 20:1 (2014), 81–88.
71. [71] Darwish, M.S., Kim, W.R., Therneau, T., Gores, G.J., Rosen, C.B., Martenson, J.A., et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 56:3 (2012), 972–981.
72. [72] Osmundson, E.C., Wu, Y., Luxton, G., Bazan, J.G., Koong, A.C., Chang, D.T., Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys 91:5 (4-1-2015), 986–994.
73. Klein, J., Dawson, L.A., Jiang, H., Kim, J., Dinniwell, R., Brierley, J., et al. Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 93:1 (9-1-2015), 16–25.
74. Mendez Romero, A., Wunderink, W., van Os, R.M., Nowak, P.J., Heijmen, B.J., Nuyttens, J.J., et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys 70:5 (4-1-2008), 1447–1452.
75. [75] Hong, T.S., Wo, J.Y., Yeap, B.Y., Ben-Josef, E., McDonnell, E.I., Blaszkowsky, L.S., et al. Multi-Institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 34:5 (2-10-2016), 460–468.
76. [76] Qi, W.X., Fu, S., Zhang, Q., Guo, X.M., Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 114:3 (2015), 289–295.
77. [77] Chaudhuri, A.A., Binkley, M.S., Osmundson, E.C., Alizadeh, A.A., Diehn, M., Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 25:4 (2015), 305–312.
78. [78] Farach, A., Quesada, J., Teh, B.S., Liver regeneration following repeat SBRT. J Gastrointest Oncol 6:2 (2015), E2–E6.
79. [79] Lo, C.H., Huang, W.Y., Lin, K.T., Lin, M.J., Lin, T.P., Jen, Y.M., Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma. J Gastroenterol Hepatol 29:11 (2014), 1919–1925.
80. [80] Chin, P.L., Chu, D.Z., Clarke, K.G., Odom-Maryon, T., Yen, Y., Wagman, L.D., Ethnic differences in the behavior of hepatocellular carcinoma. Cancer 85:9 (5-1-1999), 1931–1936.